Differential virus restriction patterns of rhesus macaque and human APOBEC3A: Implications for lentivirus evolution

Virology

Volumn 419, Issue 1, 2011, Pages 24-42

  Schmitt, Kimberly ^a   Guo, Kejun ^b   Algaier, Malinda ^a   Ruiz, Autumn ^a   Cheng, Fang ^a   Qiu, Jianming ^a   Wissing, Silke ^d   Santiago, Mario L ^b,c   Stephens, Edward B ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

APOBEC3A; Evolution; HIV 1; Rhesus macaques; SHIV; Vif; Virus restriction

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; CYTIDINE DEAMINASE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROPOSON; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL HOMOLOGY; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTIDINE DEAMINASE; DEPENDOVIRUS; EVOLUTION, MOLECULAR; GENE EXPRESSION PROFILING; HIV; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; RETROELEMENTS; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENO-ASSOCIATED VIRUS - 2; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80052459458     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.07.017     Document Type: Article

References (88)

1. Abe H., Ochi H., Maekawa T., Hatakeyama T., Tsuge M., Kitamura S., Kimura T., Miki D., Mitsui F., Hiraga N., Imamura M., Fujimoto Y., Takahashi S., Nakamura Y., Kumada H., Chayama K. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. Hepatol. Res. 2009, 39:1159-1168.
2. Aguiar R.S., Lovsin N., Tanuri A., Peterlin B.M. Vpr.A3A chimera inhibits HIV replication. J. Biol. Chem. 2008, 283:2518-2525.
3. Babushok D.V., Kazazian H.H. Progress in understanding the biology of the human mutagen LINE-1. Hum. Mutat. 2007, 28:527-539.
4. Baumert T.F., Rosler C., Malim M.H., von Weizsäcker F. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007, 46:682-689.
5. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 2004, 14:1392-1406.
6. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4:e1000231.
7. Bogerd H.P., Wiegand H.L., Doehle B.P., Lueders K.K., Cullen B.R. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 2006, 34:89-95.
8. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K.S., Moran J.V., Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8780-8785.
9. Bonvin M., Greeve J. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. J. Gen. Virol. 2007, 88:3270-3274.
10. Bonvin M., Achemann F., Greeve I., Stroka D., Keogh A., Inderbitzin D., Candinas D., Sommer P., Wain-Hobson S., Vartanian J.P., Greeve J. Interferon-inducible expression of APOBEC3C editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006, 43:1364-1374.
11. Brouha B., Schustak J., Badge R.M., Lutz-Prigge S., Farley A.H., Moran J.V., Kazazian H.H. Hot L1s account for the bulk of retrotransposition in the human population. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5280-5285.
12. Bulliard T., Narvaiza I., Bertero A., Peddi S., Röhrig U.F., Oritz M., Zoete V., Castro-Diaz N., Turelli P., Telenti A., Michielin O., Weitzman M.D., Trono D. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J. Virol. 2011, 85:1765-1776.
13. Celico L., Pham P., Calabrese P., Goodman M.F. APOBEC3G DNA deaminase acts processively 3'-5' on single stranded DNA. Nat. Struct. Mol. Biol. 2006, 13:392-399.
14. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 2006, 16:480-485.
15. Chiu Y.L., Greene W.C. APOBEC3G: an intracellular centurion. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2009, 364:689-703.
16. Conticello S.G., Thomas C.J., Petersen-Mahrt S.K., Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Biol. Evol. 2005, 22:367-377.
17. Dang Y., Wang X., Esselman W.J., Zheng Y.H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 2006, 80:10522-10533.
18. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74:8358-8367.
19. Doehle B.P., Schafer A., Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005, 339:281-288.
20. Goila-Gaur R., Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51.
21. Goila-Gaur R., Khan M.A., Miyagi E., Kao S., Strebel K. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 2007, 4:61.
22. Guo F., Cen S., Niu M., Saadatmand J., Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 2006, 80:11710-11722.
23. Guo F., Cen S., Niu M., Yang Y., Gorelick R.J., Kleiman L. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 2007, 81:11322-11331.
24. Harari A., Ooms M., Mulder L.C., Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 2009, 83:295-303.
25. Henry M., Guètard D., Suspène R., Rusniok C., Wain-Hobson S., Vartanian J.P. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One 2009, 4:e4277.
26. Holmes R.K., Malim M.H., Bishop K.N. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem. Sci. 2007, 32:118-128.
27. Holmes R.K., Koning F.A., Bishop K.N., Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282:2587-2595.
28. Huthoff H., Malim M.H. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology 2005, 334:147-153.
29. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007, 35:7096-7108.
30. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
31. Kakimoto W.M., Gettie A., Smith S., Donahoe S.M., Jin X., Marx P., Connor R., Nixon D.F. Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursors. Immunol. Lett. 1999, 66:35-140.
32. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 2003, 77:11398-11407.
33. Köck J., Blum H.E. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C, and APOBEC3H. J. Gen. Virol. 2008, 89:1184-1191.
34. Koning F.A., Newman E.N., Kim E.Y., Kunstman K.J., Wolinsky S.M., Malim M.H. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 2009, 83:9474-9485.
35. Kroutter E.N., Belancio V.P., Wagstaff B.J., Roy-Engel A.M. The RNA polymerase dictates ORF1 requirement and timing of LINE and SINE retrotransposition. PLoS Genet. 2009, 5:e1000458.
36. Landry S., Narvaiza I., Linfesty D.C., Weitzman M.D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 2011.
37. Langlois M.A., Beale R.C., Conticello S.G., Neuberger M.S. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 2005, 33:1913-1923.
38. LaRue R.S., Andresdottir V., Blanchard Y., Conticello S.G., Derse D., Emerman M., Greene W.C., Jonsson S.R., Landau N.R., Lochelt M., Malik H.S., Malim M.H., Munk C., O'Brien S.J., Pathak V.K., Strebel K., Wain-Hobson S., Xu Y.F., Yuhki N., Harris R.S. Guidelines for naming nonhuman APOBEC3 genes and proteins. J. Virol. 2009, 83:494-497.
39. Li X.Y., Guo F., Zhang L., Kleiman L., Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 2007, 282:32065-32074.
40. Li M.M., Wu L.I., Emerman M. The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 2010, 84:88-95.
41. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 2004, 14:1385-1391.
42. Liu Z.Q., Muhkerjee S., Sahni M., McCormick-Davis C., Leung K., Li Z., Gattone V.H., Tian C., Doms R.W., Hoffman T.L., Raghavan R., Narayan O., Stephens E.B. Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology 1999, 260:295-307.
43. Liu B., Yu X., Luo K., Yu Y., Yu X.F. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 2004, 78:2072-2081.
44. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 2007, 81:7238-7248.
45. Mahieux R., Suspène R., Delebecque F., Henry M., Schwartz O., Wain-Hobson S., Vartanian J.P. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 2005, 86:2489-2494.
46. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9:1398-1403.
47. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 2004, 279:7792-7798.
48. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Lower J., Cichutek K., Flory E., Schumann G.G., Munk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 2006, 281:22161-22172.
49. Narvaiza I., Linfesty D.C., Greener B.N., Hakata Y., Pintel D.J., Logue E., Landau N.R., Weitzman M.D. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 2009, 5:e1000439.
50. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15:166-170.
51. Noguchi C., Hiraga N., Mori N., Tsuge M., Imamura M., Takahashi S., Fujimoto Y., Ochi H., Abe H., Maekawa T., Yatsuji H., Shirakawa K., Takaori-Kondo A., Chayama K. Dual effect of APOBEC3G on hepatitis B virus. J. Gen. Virol. 2007, 88:432-440.
52. OhAinle M., Kerns J.A., Li M.M., Malik H.S., Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 2008, 11:249-259.
53. Ooms M., Majdak S., Seibert C.W., Harari A., Simon V. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J. Virol. 2010, 84:7961-7969.
54. Ostertag E.M., Prak E.T., DeBerardinis R.J., Moran J.V., Kazazian H.H. Determination of L1 retrotransposition kinetics in cultured cells. Nucleic Acids Res. 2000, 28:1418-1423.
55. Paprotka T., Venkatachari N.J., Chaipan C., Burdick R., Delviks-Frankenberry K.A., Hu W.S., Pathak V.K. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol. 2010, 84:5719-5729.
56. Perkovic M., Schmidt S., Marino D., Russell R.A., Stauch B., Hofmann H., Kopietz F., Kloke B.P., Zielonka J., Ströver H., Hermle J., Lindemann D., Pathak V.K., Schneider G., Löchelt M., Cichutek K., Münk C. Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J. Biol. Chem. 2009, 284:5819-5826.
57. Platt E.J., Bilska M., Kozak S.L., Kabat D., Montefiori D.C. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 2009, 83:8289-8292.
58. Qiu J., Pintel D.J. The adeno-associated virus type 2 rep protein regulates RNA processing via interaction with the transcription template. Mol. Cell. Biol. 2002, 22:3639-3652.
59. Rangwala S.H., Kazazian H.H. The L1 retrotransposition assay: a retrospective and toolkit. Methods 2009, 49:219-226.
60. Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L., Harris R.S. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 2010, 38:4274-4284.
61. Rhesus Macaque Genome Sequencing and Analysis Consortium Evolutionary and biomedical insights from the rhesus macaque genome. Science 2007, 16:222-234.
62. Russell R.A., Moore M.D., Hu W.S., Pathak V.K. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 2009, 13:6-16.
63. Sawyer S.L., Emerman M., Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2:E275.
64. Schmitt K., Hill M.S., Ruiz A., Culley N., Pinson D.M., Wong S.W., Stephens E.B. Mutations in the highly conserved SLQXLA motif of Vif results in a simian-human immunodeficiency virus results in less pathogenic virus and is associated with G to A mutations in the viral genome. Virology 2009, 383:62-72.
65. Schmitt K., Liu Q., Hill M.S., Ruiz A., Culley N., Pinson D.M., Wong S.W., Stephens E.B. Comparison of the pathogenicity of simian-human immunodeficiency viruses expressing Vif proteins with mutation of the SLQYLA and HCCH domains in macaques. Virology 2010, 404:87-203.
66. Schröfelbauer B., Senger T., Manning G., Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 2006, 80:5984-5991.
67. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
68. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9:1404-1407.
69. Smith J.L., Pathak V.K. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 2010, 84:12599-12608.
70. Sova P., Volsky D.J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type-1. J. Virol. 1993, 67:6322-6326.
71. Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Na.t Struct. Mol. Biol. 2010, 17:222-229.
72. Strebel K. APOBEC3G & HTLV-1: inhibition without deamination. Retrovirology 2005, 2:37.
73. Sui Y., Zhu Q., Gagnon S., Dzutsev A., Terabe M., Vaccari M., Venzon D., Klinman D., Strober W., Kelsall B., Franchini G., Belyakov I.M., Berzofsky J.A. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9843-9848.
74. Takeuchi Y., McClure M.O., Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 2008, 82:12585-12588.
75. Turelli P., Mangeat B., Jost S., Vianin S., Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
76. Vartanian J.P., Guétard D., Henry M., Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 2008, 320:230-233.
77. Virgen C.A., Hatziioannou T. Antiretroviral activity and vif sensitivity of rhesus macaque APOBEC3 proteins. J. Virol. 2007, 81:13932-13937.
78. von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral cDNA synthesis in infected cells. J. Virol. 1993, 67:4945-4955.
79. Wang X., Abudu A., Son S., Dang Y., Venta P.J., Zheng Y.H. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type-1 activity. J. Virol. 2011, 85:3142-3152.
80. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
81. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif protein. EMBO J. 2004, 23:2451-2458.
82. Xiao X., Li J., Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenvirus. J. Virol. 1998, 72:2224-2232.
83. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
84. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11:435-442.
85. Zennou V., Bieniasz P.D. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 2006, 25:31-40.
86. Zhang W., Zhang X., Tian C., Wang T., Sarkis P.T., Fang Y., Zheng S., Yu X.F., Xu R. Cytidine deaminase APOEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell. Microbiol. 2008, 10:112-121.
87. Zheng Y.H., Peterlin B.M. Intracellular immunity to HIV-1:newly defined retroviral battles inside infected cells. Retrovirology 2005, 13:2-25.
88. Zheng Y.H., Irwin D., Krosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:6073-6076.